StreetInsider.com News Articles

AstraZeneca (AZN) PT Lowered to $205 at Morgan Stanley

Thu, 16 Jul 2026 06:46:33 -0400

Morgan Stanley analyst Sarita Kapila lowered the price target on AstraZeneca (NASDAQ: AZN) to $205.00 (from $220.00) while maintaining a Overweight rating.

AstraZeneca (AZN:LN) (AZN) PT Lowered to GBP153 at Morgan Stanley

Thu, 16 Jul 2026 04:30:44 -0400

Morgan Stanley analyst Sarita Kapila lowered the price target on AstraZeneca (AZN:LN) (NASDAQ: AZN) to GBP153.00 (from GBP165.00) while maintaining a Overweight rating.

AstraZeneca (AZN:LN) (AZN) PT Lowered to GBP153 at Morgan Stanley

Thu, 16 Jul 2026 04:30:44 -0400

Morgan Stanley analyst Sarita Kapila lowered the price target on AstraZeneca (AZN:LN) (NASDAQ: AZN) to GBP153.00 (from GBP165.00) while maintaining a Overweight rating.

AstraZeneca (AZN:LN) (AZN) PT Lowered to GBP153 at Morgan Stanley

Thu, 16 Jul 2026 04:30:44 -0400

Morgan Stanley analyst Sarita Kapila lowered the price target on AstraZeneca (AZN:LN) (NASDAQ: AZN) to GBP153.00 (from GBP165.00) while maintaining a Overweight rating.

AstraZeneca (AZN:LN) (AZN) PT Lowered to GBP153 at Morgan Stanley

Thu, 16 Jul 2026 04:30:44 -0400

Morgan Stanley analyst Sarita Kapila lowered the price target on AstraZeneca (AZN:LN) (NASDAQ: AZN) to GBP153.00 (from GBP165.00) while maintaining a Overweight rating.

Alnylam Pharmaceuticals (ALNY) PT Raised to $485 at H.C. Wainwright

Tue, 14 Jul 2026 06:55:27 -0400

(Updated - July 14, 2026 6:55 AM EDT)

H.C. Wainwright analyst Patrick Trucchio raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $485.00 (from $470.00) while maintaining a Buy rating.

The analyst commented: "On July 9, AstraZeneca and Ionis Pharmaceuticals announced that the Phase 3 CARDIO-TTRansform trial (n=1,432) evaluating eplontersen, an antisense oligonucleotide (ASO) in ATTR-CM, missed its primary endpoint, a composite of cardiovascular (CV) mortality and recurrent CV clinical events through Week 140. We view the CARDIO-TTRansform failure as idiosyncratic to eplontersen rather than a read-through to the silencer mechanism, leaving Alnylam's AMVUTTRA (vutrisiran) as the only ATTR therapy labeled

Alnylam Pharmaceuticals (ALNY) PT Raised to $485 at H.C. Wainwright

Tue, 14 Jul 2026 06:55:27 -0400

(Updated - July 14, 2026 6:55 AM EDT)

H.C. Wainwright analyst Patrick Trucchio raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $485.00 (from $470.00) while maintaining a Buy rating.

Alnylam Pharmaceuticals (ALNY) PT Raised to $485 at H.C. Wainwright

Tue, 14 Jul 2026 06:55:27 -0400

(Updated - July 14, 2026 6:55 AM EDT)

H.C. Wainwright analyst Patrick Trucchio raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $485.00 (from $470.00) while maintaining a Buy rating.

Form 6-K ASTRAZENECA PLC For: Jul 14

Tue, 14 Jul 2026 06:37:00 -0400

si-local-file:///var/storage/secattach/20260714/26764474.html

Form 6-K ASTRAZENECA PLC For: Jul 14

Tue, 14 Jul 2026 06:37:00 -0400

si-local-file:///var/storage/secattach/20260714/26764474.html

Form 6-K ASTRAZENECA PLC For: Jul 14

Tue, 14 Jul 2026 06:37:00 -0400

si-local-file:///var/storage/secattach/20260714/26764474.html

AstraZeneca licenses sunvozertinib from Dizal for $600M upfront

Tue, 14 Jul 2026 05:52:48 -0400

AstraZeneca (NASDAQ: AZN) has entered into an exclusive license agreement with Dizal Pharmaceutical Co., Ltd to acquire worldwide rights to develop and commercialize Zegfrovy (sunvozertinib), an oral irreversible epidermal growth factor receptor (EGFR) inhibitor for lung cancer patients.

Under the terms of the agreement, AstraZeneca will pay Dizal $600 million upfront, with up to $900 million in additional payments tied to development, regulatory, and sales-related milestones. Dizal will also receive tiered royalties on global Zegfrovy sales. The transaction is expected to close in the second half of 2026, subject to regulatory clearances and customary closing conditions. AstraZeneca stated the deal does

AstraZeneca licenses sunvozertinib from Dizal for $600M upfront

Tue, 14 Jul 2026 05:52:48 -0400

AstraZeneca licenses sunvozertinib from Dizal for $600M upfront

Tue, 14 Jul 2026 05:52:48 -0400

AstraZeneca licenses sunvozertinib from Dizal for $600M upfront

Tue, 14 Jul 2026 05:52:48 -0400

AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'

Mon, 13 Jul 2026 07:06:54 -0400

Investing.com -- HSBC has downgraded AstraZeneca (LON:AZN) (NASDAQ:AZN) to Hold from Buy and slashed its price target to 13,750 pence from 16,500 pence, after the drugmaker’s Wainua trial failed to meet its primary endpoint in a Phase 3 study.

“Wainua setback impairs our bull case, given the more difficult catalyst path ahead,” HSBC analyst Rajesh Kumar said in a note.

Shares in the British pharma giant fell 1.3% in London trading, while its U.S.-listed shares shed 1.5% in the premarket trade.

Success in the CARDIO-TTR trial had underpinned HSBC’s positive view on the stock, Kumar noted, representing a market opportunity of more than

AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'

Mon, 13 Jul 2026 07:06:54 -0400

“Wainua setback impairs our bull case, given the more difficult catalyst path ahead,” HSBC analyst Rajesh Kumar said in a note.

Shares in the British pharma giant fell 1.3% in London trading, while its U.S.-listed shares shed 1.5% in the premarket trade.

Success in the CARDIO-TTR trial had underpinned HSBC’s positive view on the stock, Kumar noted, representing a market opportunity of more than

BridgeBio Pharma (BBIO) PT Raised to $120 at H.C. Wainwright